FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation
FDA批准摘要:奥鲁西地尼用于治疗伴有异柠檬酸脱氢酶1突变的复发或难治性急性髓系白血病成人患者
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2196
Woods, Ashley C; Norsworthy, Kelly J; Choe, Moran; Gehrke, Brenda J; Chen, Haiyan; Vallejo, Jonathon; Pan, Lili; Jiang, Xiling; Li, Hongshan; Kraft, Jeffrey; Liu, Jiang; Charlab, Rosane; Okusanya, Olanrewaju O; Booth, Brian; Pazdur, Richard; Theoret, Marc R; Angelo de Claro, R